Journal of the American Society of Nephrology
2007 JASN IMPACT FACTOR 7.111 HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP 
    advanced
CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION


This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mourad, G.
Right arrow Articles by Argiles, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mourad, G.
Right arrow Articles by Argiles, A.

Journal of the American Society of Nephrology, Vol 7, 798-804, Copyright © 1996 by American Society of Nephrology

REGULAR ARTICLES

Renal transplantation relieves the symptoms but does not reverse beta 2- microglobulin amyloidosis

G Mourad and A Argiles
Department of Nephrology, University Hospital Lapeyronie, Montpellier, France.

Renal transplantation is considered to be the treatment of choice of dialysis-related beta 2-microglobulin amyloidosis (DRA), as it provides near-normal serum levels of beta 2-microglobulin and obviates the need for dialysis. However, the long-term outcome of DRA after transplantation has not been fully assessed, and its evolution after transplant failure has not been reported. This study examined 17 patients with histologically confirmed DRA who underwent kidney transplantation and had a dialysis-free follow-up period in excess of 1 yr. Immunosuppressive treatment included low-dose prednisolone, cyclosporine, and/or azathioprine. Symptoms related to DRA were sought at every outpatient visit, and bone x-rays were performed at time of transplantation and annually thereafter. The number and size of the bone cysts were determined. Most of the DRA symptoms, and particularly shoulder stiffness, disappeared within the first wk after transplantation and this persisted throughout the transplant follow-up period (58.5 +/- 9 months). However, the number of bone cysts remained remarkably constant even in those patients with still-functioning grafts (12 +/- 7.5 and 12.1 +/- 7.7, before and at last transplantation follow-up examination, respectively). Beta 2-microglobulin amyloid was found to be present in one patient operated on for hip fracture 2 yr after receiving a well-functioning transplant. Seven patients experienced graft failure and returned to dialysis after 47 +/- 39 months of transplantation. Severe DRA symptoms reappeared strikingly early after resuming hemodialysis, and five out of the seven patients required surgery for carpal tunnel syndrome, three of them within the first yr (mean, 17 +/- 12 months). The number of cysts significantly increased from 17 +/- 11 to 21 +/- 11 during the second dialysis period. These findings provide further evidence suggesting that although the clinical expression of DRA is arrested during transplantation, the anatomical lesions and the pathological processes underlying it are unlikely to be reversed.


This article has been cited by other articles:


Home page
 J. Am. Soc. Nephrol.Home page
R. VANHOLDER and R. DE SMET
Pathophysiologic Effects of Uremic Retention Solutes
J. Am. Soc. Nephrol., August 1, 1999; 10(8): 1815 - 1823.
[Full Text]


HOME CURRENT ISSUE ARCHIVES JASN Express ONLINE SUBMISSION AUTHOR INFO
EDITORIAL BOARD SUBSCRIBE FEEDBACK ALERTS HELP

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673